Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Functional genomics in pancreatic β cells: recent advances in gene deletion and genome editing technologies for diabetes research.

Title: Functional genomics in pancreatic β cells: recent advances in gene deletion and genome editing technologies for diabetes research.
Authors: Hu, M; Cherkaoui, I; Misra, S; Rutter, GA
Contributors: MRC Programme Grant; Medical Research Council (MRC); Wellcome Trust; INNOVATIVE MEDICINES INITIATIVE; Diabetes UK; Biotechnology and Biological Sciences Research Council (BBSRC); The Royal Society; European Foundation for the Study of Diabetes; Sun Pharmaceutical Industries Limited
Source: 20 ; 1
Publication Year: 2020
Collection: Imperial College London: Spiral
Subject Terms: beta cell; genome editing; genome-wide association studies; maturity onset of diabetes of the young; mouse models; stem cells; 1103 Clinical Sciences; 1111 Nutrition and Dietetics
Subject Geographic: Switzerland
Description: The inheritance of variants that lead to coding changes in, or the mis-expression of, genes critical to pancreatic beta cell function can lead to alterations in insulin secretion and increase the risk of both type 1 and type 2 diabetes. Recently developed clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) gene editing tools provide a powerful means of understanding the impact of identified variants on cell function, growth, and survival and might ultimately provide a means, most likely after the transplantation of genetically "corrected" cells, of treating the disease. Here, we review some of the disease-associated genes and variants whose roles have been probed up to now. Next, we survey recent exciting developments in CRISPR/Cas9 technology and their possible exploitation for β cell functional genomics. Finally, we will provide a perspective as to how CRISPR/Cas9 technology may find clinical application in patients with diabetes.
Document Type: article in journal/newspaper
Language: English
Relation: Front Endocrinol (Lausanne); http://hdl.handle.net/10044/1/84092; MR/R022259/1; MR/R010676/1; 212625/Z/18/Z; 097816/Z/11/ZR; 105603/Z/14/Z; 098424/Z/12/ZR; MR/K001981/1; MR/N020472/1; MR/L02036X/1; 115881; 15 / 0005275; MR/M012646/1; R26199/CN001; 15821; BB/J015873/1; 12/0004601; WM100078; MR/K023667/1; N/A; 15/0005374; BDA number 13/0004672; 13/0004672
DOI: 10.3389/fendo.2020.576632
Availability: http://hdl.handle.net/10044/1/84092; https://doi.org/10.3389/fendo.2020.576632
Rights: © 2020 Hu, Cherkaoui, Misra and Rutter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. ; http://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.994E4085
Database: BASE